Pulmonx price target lowered to $8 from $12 at Lake Street

Lake Street analyst Frank Takkinen lowered the firm’s price target on Pulmonx (LUNG) to $8 from $12 and keeps a Buy rating on the shares. Despite a “strong” Q2, Pulmonx guided 2025 revenue growth down to 7%-10% from the previous 15%-17% growth expectation, notes the analyst, who calls the guide down “a prudent reset.”